Par Drugs (PAR) | Stock Overview & Key Data
Par Drugs Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹348.45 on December 2, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Mar 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Par Drugs
PAR
|
1.36B Small-cap | 9.88% | 7.00% | 7.59% | -7.96% | -8.14% | -11.42% | -57.49% | 26.63% | 250.22% | 250.22% | 250.22% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Sun Pharma Advanced
SPARC
|
46.75B Small-cap | 12.49% | 39.95% | 100.62% | 67.89% | 69.61% | 34.88% | 14.54% | -3.55% | -20.47% | 148.26% | -23.02% |
|
Innova Captab
INNOVACAP
|
41.43B Small-cap | 8.95% | 10.45% | 34.08% | 34.58% | 28.37% | 3.87% | 74.08% | 74.08% | 74.08% | 74.08% | 74.08% |
|
Gujarat Themis
GUJTHEM
|
35.41B Small-cap | -4.89% | 4.00% | 38.98% | -1.40% | -12.59% | 15.75% | 76.92% | 76.92% | 76.92% | 76.92% | 76.92% |
Ownership & Short Interest
Calculate Your Par Drugs Investment Returns
Long-Term Investment Performance Analysis
Par Drugs stock price in May 2019 was ₹24.75, A ₹1,000.00 lump sum investment in Par Drugs made 7 years ago would be worth approximately ₹3,773.74 today, representing a outstanding return of 277.37%. This translates to an annualized return (CAGR) of 20.72%.
7 Years Investment Scenario (May 2019 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is PAR's 52-week high and low?
- In the last 52 weeks, Par Drugs reached a high of ₹122.43 (on September 18, 2025) and a low of ₹78.05 (on March 30, 2026).
- What is the market cap and P/E ratio for PAR?
- Curious about Par Drugs's size and valuation? Its market capitalization stands at 1.36B. When it comes to valuation, the P/E ratio (trailing twelve months) is 10.15, and the forward P/E (looking ahead) is N/A.
- Does PAR pay dividends? If so, what's the yield?
- As for dividends, Par Drugs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Par Drugs's main competitors or similar companies to consider before investing?
When looking at Par Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Sun Pharma Advanced
SPARC46.75B Healthcare Drug Manufacturers - Specialty & Generic 34.88% 14.54% Innova Captab
INNOVACAP41.43B Healthcare Drug Manufacturers - Specialty & Generic 3.87% 74.08% Gujarat Themis
GUJTHEM35.41B Healthcare Drug Manufacturers - Specialty & Generic 15.75% 76.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Par Drugs and Chemicals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Par Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 14.47%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at 56.21%.
- What is the recent revenue and earnings growth for PAR?
- Looking at Par Drugs's growth, its revenue over the trailing twelve months (TTM) was INR1B. Compared to the same quarter last year (YoY), quarterly revenue grew by -2.10%, and quarterly earnings saw a YoY growth of -55.60%.
- How much of PAR stock is held by insiders and institutions?
- Wondering who owns Par Drugs stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.